NCT03396471 - Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

August 12, 2021

Study Completion Date

March 2, 2023

Conditions

Carcinoma, Unspecified Site

Interventions

DRUG

Pembrolizumab

200mg IV at day -21, then day 1 of each 21-day cycle for a maximum of 24 continuous months of Pembrolizumab (35 cycles) from Cycle 1 Day 1 (C1D1) can be administered.

RADIATION

External Beam Radiation Therapy

20-30 Gy over five fractions for up to two cycles.

Trial Locations (2)

55905

Mayo Clinic, Rochester

77030

MD Anderson Cancer Center, Houston